Biohaven Appoints John Tilton as Chief Commercial Officer

Share Article

The Board of Directors of Biohaven Pharmaceutical Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as Chief Commercial Officer. Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications.

The Board of Directors of Biohaven Pharmaceutical Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has over 20 years of experience commercializing drug products and leading global pharmaceutical business units. 

Mr. Tilton played a central role in the successful global launches of Soliris, as well as building operational infrastructure for four orphan indication launches in over 30 countries for Alexion. Previously, Mr. Tilton held leadership roles of increasing responsibility at Pfizer, Agouron and Sanofi with therapeutic focus in the orphan, oncology and specialty markets.  In this newly created position, Mr. Tilton will provide strategic leadership from a commercial background and lead Biohaven’s commercialization activities. Mr. Tilton will also serve as a member of Biohaven’s executive leadership team. 

"John’s proven commercialization leadership in life sciences will complement our strong research and development organization, and ensure that we maximize the market success of our assets. John is a highly talented senior business executive who brings a strong commitment to science and patient-centered focus to the commercial aspects of our organization.  He has been a leader and integral part of many global launches at major biopharmaceutical companies," said Vlad Coric, MD, Chief Executive Officer at Biohaven Pharmaceuticals.  Dr. Coric added, "I am very pleased to have John join our executive leadership team and assume responsibility for a broad range of business activities."

"It is exciting to be joining Biohaven at such an important time and I look forward to working with the team to maximize our commercial opportunities in the U.S. and around the world as well as bringing new therapies to patients with neurodegenerative diseases.” said John Tilton, Biohaven Chief Commercial Officer.

Declan Doogan M.D., Chairman of Biohaven’s Board of Directors, added, “John’s impressive experience in successfully launching and commercializing drugs to treat orphan illnesses is a critical skill to add to the executive leadership team as Biohaven evolves from a research and development company into a global biopharmaceutical company with an integrated commercial organization. John will be responsible for leading and executing our global commercial strategy to bring our investigational agents to patients as quickly as possible.”

Biohaven is preparing for the potential for near term commercialization upon successful completion of its clinical stage assets.

About Biohaven

Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc. (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), Yale University and other private investors.  The company’s first drug candidate, BHV-0223, is a novel formulation of a glutamate-modulating agent, being developed under FDA 505(b)(2) guidelines. The FDA cleared the company’s Investigational New Drug application (IND) in August 2015. Biohaven has completed a PK study in humans and is planning to launch a pivotal bioequivalence study by 4Q2016. Biohaven’s second compound, BHV-4157, a prodrug form of a glutamate modulating agent, is being developed as a New Chemical Entity (NCE). The company plans to advance other glutamatergic approaches and is actively exploring licenses for additional compounds.
 
For further information, contact Dr. Vlad Coric, the Chief Executive Officer, at Vlad(dot)Coric(at)biohavenpharma(dot)com

http://www.biohavenpharma.com

+1 203-404-0410

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe,” “anticipate,” “will,” “plan,” “could,” “may” and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. Vlad Coric, Chief Executive Officer
Visit website